Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Drugs such as thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating women who have epithelial ovarian cancer that has not responded to previous therapy.

Key facts

Study ID

NCT00016224

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-01-01

Expected to finish

2004-03-01

Last updated by the study team

2013-06-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.